A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.
Quick Facts
What This Study Found
Thymosin β4 was well tolerated with no serious adverse events reported across doses.
Key Numbers
How They Did This
The study involved a randomized, double-blind design with healthy volunteers receiving single and multiple doses of thymosin β4.
Why This Research Matters
Understanding the safety of thymosin β4 is crucial for its potential use in treating serious conditions like heart attacks. This study lays the groundwork for future research.
What This Study Doesn't Tell Us
The study was limited to healthy volunteers, and results may not apply to patients with specific conditions.
Trust & Context
- Original Title:
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.
- Published In:
- Journal of cellular and molecular medicine, 25(17), 8222-8228 (2021)
- Authors:
- Wang, Xinghe, Liu, Long, Qi, Lu, Lei, Chunpu, Li, Pu, Wang, Yu, Liu, Chen, Bai, Haihong, Han, Chengquan, Sun, Yinjian, Liu, Jincan
- Database ID:
- RPEP-05859
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05859APA
Wang, Xinghe; Liu, Long; Qi, Lu; Lei, Chunpu; Li, Pu; Wang, Yu; Liu, Chen; Bai, Haihong; Han, Chengquan; Sun, Yinjian; Liu, Jincan. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.. Journal of cellular and molecular medicine, 25(17), 8222-8228. https://doi.org/10.1111/jcmm.16693
MLA
Wang, Xinghe, et al. "A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.." Journal of cellular and molecular medicine, 2021. https://doi.org/10.1111/jcmm.16693
RethinkPeptides
RethinkPeptides Research Database. "A first-in-human, randomized, double-blind, single- and mult..." RPEP-05859. Retrieved from https://rethinkpeptides.com/research/wang-2021-a-firstinhuman-randomized-doubleblind
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.